TELA Bio Q4 revenue $11.6M (+39% YoY); FY2023 guidance $60-65M

TELA Bio, Inc.

Full-year 2022 revenue $41.4M (+41% YoY); net loss $44.3M.
Q4 2022 gross margin 70% vs 68% a year ago; cash $42.0M at Dec 31.
OviTex revenue +26% YoY; OviTex PRS +92% YoY; new NIVIS and OviTex LPR launches.
FY2023 revenue guidance $60-65M (45-57% growth).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TELA Bio, Inc. reported Full year 2023 results: revenue $60 million to $65 million. Guidance initiated.

Period: Full year 2023
Revenue: $60 million to $65 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Full year 2023 revenue is projected to range from $60 million to $65 million, reflecting growth of 45% to 57% over full year 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TELA Bio, Inc. reported the fourth quarter of 2022 results: revenue $11.6 million, net income $10.0 million.

Period: the fourth quarter of 2022
Revenue: $11.6 million
Net income: $10.0 million
Result: reported results

Exact text from the filing

Revenue was $11.6 million in the fourth quarter of 2022, an increase of 39% compared to the same period in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TELA Bio, Inc. reported the full year ended December 31, 2022 results: revenue $41.4 million, net income $44.3 million.

Period: the full year ended December 31, 2022
Revenue: $41.4 million
Net income: $44.3 million
Result: reported results

Exact text from the filing

Revenue was $41.4 million for the full year 2022, an increase of 41% compared to the full year 2021.

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

TELA Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-035061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.